WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, May 29, 2007

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L9	L8 and @py<2002	2
☐	L8	L7 and antagonist	88
☐	L7	L6 and bicyclic	88
☐	L6	vegf and neuropilin 1	411
	DB=USPT,PGPB; PLUR=YES; OP=ADJ		
☐	L5	ZACHARY-IAN!	4
☐	L4	LOEHR-MARIANNE!	1
☐	L3	SELWOOD-DAVID!	7
☐	L2	SELWOOD-DAVID!	7
☐	L1	SELWOOD-DAVID!	7

END OF SEARCH HISTORY

Case # 10/507,463.

WEST
5/29/07
AD

FILE 'BIOSIS' ENTERED AT 10:28:51 ON 29 MAY 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 10:28:51 ON 29 MAY 2007

Case #10/507,463.
STN (MEDLINE, BIOSIS)
AD
5/29/07

=> s vegf and neuropilin
L1 698 VEGF AND NEUROPILIN

=> s l1 and bicyclic
L2 2 L1 AND BICYCLIC

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3 1 DUP REM L2 (1 DUPLICATE REMOVED)

=> disp l3 ibib abs 1-1

L3 ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
DUPLICATE 1
ACCESSION NUMBER: 2006:465243 BIOSIS
DOCUMENT NUMBER: PREV200600471119
TITLE: Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor Exon 8 for NP-1 binding and role of NP-1 in KDR signaling.
AUTHOR(S): Jia, Haiyan; Bagherzadeh, Azadeh; Hartzoulakis, Basil; Jarvis, Ashley; Loehr, Marianne; Shaikh, Shaheda; Aqil, Rehan; Cheng, Lili; Tickner, Michelle; Esposito, Diego; Harris, Richard; Driscoll, Paul C.; Selwood, David L.; Zachary, Ian C. [Reprint Author]
CORPORATE SOURCE: Univ Coll London, BHF Labs, Dept Med, Ctr Cardiovasc Biol and Med, 5 Univ St, London WC1E 6JJ, UK
i.zachary@ucl.ac.uk
SOURCE: Journal of Biological Chemistry, (MAY 12 2006) Vol. 281, No. 19, pp. 13493-13502.
CODEN: JBCHA3. ISSN: 0021-9258.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 20 Sep 2006
Last Updated on STN: 20 Sep 2006

AB Neuropilin- 1 (NP- 1) is a receptor for vascular endothelial growth factor- A(165)(VEGF- A(165)) in endothelial cells. To define the role of NP- 1 in the biological functions of VEGF, we developed a specific peptide antagonist of VEGF binding to NP- 1 based on the NP- 1 binding site located in the exon 7- and 8- encoded VEGF- A165 domain. The bicyclic peptide, EG3287, potently (K-i 1.2 mu M) and effectively (> 95% inhibition at 100 mu M) inhibited VEGF- A(165) binding to porcine aortic endothelial cells expressing NP- 1 (PAE/ NP- 1) and breast carcinoma cells expressing only NP- 1 receptors for VEGF- A, but had no effect on binding to PAE/ KDR or PAE/ Flt- 1. Molecular dynamics calculations, a nuclear magnetic resonance structure of EG3287, and determination of stability in media, indicated that it constitutes a stable subdomain very similar to the corresponding region of native VEGF- A(165). The C terminus encoded by exon 8 and the three- dimensional structure were both critical for EG3287 inhibition of NP- 1 binding, whereas modifications at the N terminus had little effect. Although EG3287 had no direct effect on VEGF- A(165) binding to KDR receptors, it inhibited cross- linking of VEGF- A(165) to KDR in human umbilical vein endothelial cells co- expressing NP- 1, and inhibited stimulation of KDR and PLC- gamma tyrosine phosphorylation, activation of ERKs1/ 2 and prostanoid production. These findings characterize the first specific antagonist of VEGF- A(165) binding to NP- 1 and demonstrate that NP- 1 is

essential for optimum KDR activation and intracellular signaling. The results also identify a key role for the C- terminal exon 8 domain in VEGF- A(165) binding to NP-1.

=>

```
FILE 'CAPLUS' ENTERED AT 10:33:53 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 May 2007  VOL 146 ISS 23
FILE LAST UPDATED: 28 May 2007  (20070528/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> E LOEHR MARIANNE/IN 25
E1            1     LOEHR KLAUS/IN
E2            2     LOEHR M E/IN
E3            3 --> LOEHR MARIANNE/IN
E4            1     LOEHR MARK/IN
E5            3     LOEHR MARKUS/IN
E6            1     LOEHR MARTIN/IN
E7            8     LOEHR MATTHIAS/IN
E8            1     LOEHR NORBERT/IN
E9           17     LOEHR OSKAR/IN
E10           7     LOEHR REINHOLD/IN
E11           2     LOEHR SANDRA/IN
E12           1     LOEHR STEFAN/IN
E13           2     LOEHR SUSAN R/IN
E14           3     LOEHR TODD M/IN
E15           1     LOEHR TODD MORRIS/IN
E16           1     LOEHR VOLKER/IN
E17           1     LOEHR W/IN
E18           1     LOEHR WALTER/IN
E19           3     LOEHR WERNER/IN
E20           1     LOEHR WILHELM DIPL ING/IN
E21           1     LOEHR WILLI/IN
E22           1     LOEHR WILLY/IN
E23           1     LOEHRER LEO/IN
E24           1     LOEHRISCH INGO/IN
E25           5     LOEHRKE BERTHOLD/IN

=> S (E3) AND (VEGF)
              3 "LOEHR MARIANNE"/IN
          19462 VEGF
            173 VEGFS
          19477 VEGF
                (VEGF OR VEGFS)
L2            2 ("LOEHR MARIANNE"/IN) AND (VEGF)

=> DIS L2 1 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y
```

L2 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:796747 CAPLUS
DOCUMENT NUMBER: 139:286375
TITLE: Sequences of VEGF peptides and their use for neurodegeneration and anti-cancer therapy
INVENTOR(S): Selwood, David; Loehr, Marianne; Zachary, Ian
PATENT ASSIGNEE(S): Ark Therapeutics Ltd., UK
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082918	A1	20031009	WO 2003-GB1375	20030328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481253	A1	20031009	CA 2003-2481253	20030328
AU 2003226515	A1	20031013	AU 2003-226515	20030328
EP 1490401	A1	20041229	EP 2003-745335	20030328
EP 1490401	B1	20070425		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642979	A	20050720	CN 2003-807113	20030328
JP 2005531527	T	20051020	JP 2003-580381	20030328
AT 360644	T	20070515	AT 2003-745335	20030328
US 2006166868	A1	20060727	US 2004-507463	20040910
NO 2004004105	A	20041027	NO 2004-4105	20040927
PRIORITY APPLN. INFO.:			GB 2002-7644 A	20020402
			WO 2003-GB1375 W	20030328

ABSTRACT:
A novel peptide having the amino acid sequence SCKNTDSRCKARQLELNERTCRCDKPRR or a fragment thereof that substantially retains NP-1 antagonist activity, in cyclic form, is proposed for use in therapy. The invention also relates to the use of this peptide in neurodegeneration and anti-cancer therapy.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L2 2 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:332207 CAPLUS
DOCUMENT NUMBER: 136:350545
TITLE: VEGF peptides and their use for inhibiting angiogenesis
INVENTOR(S): Selwood, David; Zachary, Ian; Jia, Haiyan; Loehr, Marianne; Davis, Dana
PATENT ASSIGNEE(S): Ark Therapeutics Ltd., UK
SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002034767	A1	20020502	WO 2001-GB4736		20011025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2426736	A1	20020502	CA 2001-2426736		20011025
AU 2002010713	A5	20020506	AU 2002-10713		20011025
EP 1328539	A1	20030723	EP 2001-978615		20011025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
HU 200301523	A2	20031028	HU 2003-1523		20011025
HU 200301523	A3	20061128			
JP 2004512342	T	20040422	JP 2002-537757		20011025
CN 1612893	A	20050504	CN 2001-817997		20011025
NO 2003001845	A	20030424	NO 2003-1845		20030424
US 2004054143	A1	20040318	US 2003-398616		20030806
PRIORITY APPLN. INFO.:			GB 2000-26134	A	20001025
			WO 2001-GB4736	W	20011025

ABSTRACT:
A peptide having part or all of the amino acid sequence QKRKRKKSRYKSWSVP (which is part of VEGF) has the ability to inhibit angiogenesis.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> E ZACHARY IAN/IN 25

E1	1	ZACHARY ALAN E/IN
E2	1	ZACHARY BRYAN A/IN
E3	4 -->	ZACHARY IAN/IN
E4	1	ZACHARY JAMES H/IN
E5	1	ZACHARY KIMBERLY J/IN
E6	1	ZACHARY NOLD SNIDERMAN/IN
E7	4	ZACHARY RICHARD E/IN
E8	1	ZACHARY WAYNE/IN
E9	1	ZACHARZEWSKA BOGUSLAWA/IN
E10	4	ZACHARZEWSKI BOLESLAW/IN
E11	1	ZACHARZEWSKY KARIN/IN
E12	3	ZACHARZOWSKY KARIN/IN
E13	1	ZACHARZOWSKY KARL/IN
E14	2	ZACHAU CHRISTIANSEN BIRGIT/IN
E15	27	ZACHAU MARTIN/IN
E16	1	ZACHAU OTTO/IN
E17	19	ZACHAU THILO/IN
E18	1	ZACHAU WOLFGANG/IN
E19	1	ZACHAY VICTOR F/IN
E20	1	ZACHCIAL HENRYK/IN
E21	1	ZACHEISS SVEN/IN
E22	3	ZACHEJA JOHANNES/IN
E23	1	ZACHENSKA ZUZANA/IN
E24	8	ZACHER ALAN H/IN

```
E25          1     ZACHER DAVID M/IN

=> S (E3) AND (VEGF)
             4 "ZACHARY IAN"/IN
         19462 VEGF
           173 VEGFS
         19477 VEGF
                 (VEGF OR VEGFS)
L3           3 ("ZACHARY IAN"/IN) AND (VEGF)

=> DIS L3 1 TI

L3   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   VEGF-induced gene in HUVEC identified by microarray and their
     therapeutic use in angiogenesis


=> DIS L3 2 TI

L3   ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Sequences of VEGF peptides and their use for neurodegeneration
     and anti-cancer therapy


=> DIS L3 3 TI

L3   ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   VEGF peptides and their use for inhibiting angiogenesis


=> DIS L3 1 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:260099  CAPLUS
DOCUMENT NUMBER:          142:310910
TITLE:                    VEGF-induced gene in HUVEC identified by
                          microarray and their therapeutic use in angiogenesis
INVENTOR(S):              Zachary, Ian; Liu, Dan
PATENT ASSIGNEE(S):       Ark Therapeutics Ltd., UK
SOURCE:                   PCT Int. Appl., 15 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2005026206         A2    20050324    WO 2004-GB3956          20040916
     WO 2005026206         A3    20050818
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     EP 1664105            A2    20060607    EP 2004-768502          20040916
```

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.: GB 2003-21694 A 20030916
WO 2004-GB3956 W 20040916

ABSTRACT:
A product for therapeutic use in promoting angiogenesis is a gene or product identified as upregulated by VEGF (vascular endothelial growth factor). To investigate VEGF-regulated gene expression, cRNA was prepared from confluent cultures of HUVECs that had been treated with ***VEGF*** , and hybridized with Affymetrix high-d. oligonucleotide arrays representing morethan 15,000 human genes. Eighteen genes were increased >2-fold in VEGF-treated HUVECs compared with untreated controls. Transcription factors made up the largest functional group of VEGF -induced genes VEGF. VEGF induced expression of genes encoding the three related orphan nuclear receptors, NR4A1, NR4A2 and NR4A3 and genes for several cytokines and growth factors. VEGF increased expression of two ion channels: the inwardly-rectifying potassium K+ channel, Kir 2.1, and the small-conductance Cat2+-activated K+channel, SK2 or KCNN2. Several signaling mols. were induced by VEGF, of which the serine/threonine kinase Cot (mitogen-activated protein kinase kinase kinase 8), and the dual specificity phosphatases DUSP-1 (MAP kinase phosphatase 1) and DUSP-5 (also called VH3), were the most prominently expressed. Several down-regulated genes encode either cell surface proteins or proteins associated with cell-cell junctions, including the tight junction component claudin 5, the gap junction protein connexin 37, epithelial V-like antigen 1 (EVA-1) and the water channel protein aquaporin 1. VEGF also significantly decreased expression of the TNF ligand superfamily member, TRAIL and 1,2-α-mannosidase, a Golgi-associated enzyme.

=> DIS L3 2 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:796747 CAPLUS
DOCUMENT NUMBER: 139:286375
TITLE: Sequences of VEGF peptides and their use for neurodegeneration and anti-cancer therapy
INVENTOR(S): Selwood, David; Loehr, Marianne; Zachary, Ian
PATENT ASSIGNEE(S): Ark Therapeutics Ltd., UK
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082918	A1	20031009	WO 2003-GB1375	20030328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481253	A1	20031009	CA 2003-2481253	20030328
AU 2003226515	A1	20031013	AU 2003-226515	20030328

EP 1490401	A1	20041229	EP 2003-745335	20030328
EP 1490401	B1	20070425		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642979	A	20050720	CN 2003-807113	20030328
JP 2005531527	T	20051020	JP 2003-580381	20030328
AT 360644	T	20070515	AT 2003-745335	20030328
US 2006166868	A1	20060727	US 2004-507463	20040910
NO 2004004105	A	20041027	NO 2004-4105	20040927
PRIORITY APPLN. INFO.:			GB 2002-7644 A	20020402
			WO 2003-GB1375 W	20030328

ABSTRACT:
A novel peptide having the amino acid sequence SCKNTDSRCKARQLELNERTCRCDKPRR or a fragment thereof that substantially retains NP-1 antagonist activity, in cyclic form, is proposed for use in therapy. The invention also relates to the use of this peptide in neurodegeneration and anti-cancer therapy.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	22.26	33.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-4.68

FILE 'STNGUIDE' ENTERED AT 10:36:01 ON 29 MAY 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 25, 2007 (20070525/UP).

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	33.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.68

FILE 'CAPLUS' ENTERED AT 10:36:21 ON 29 MAY 2007

FILE COVERS 1907 - 29 May 2007 VOL 146 ISS 23

FILE LAST UPDATED: 28 May 2007 (20070528/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> DIS L3 3 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:332207 CAPLUS
DOCUMENT NUMBER: 136:350545
TITLE: VEGF peptides and their use for inhibiting angiogenesis
INVENTOR(S): Selwood, David; Zachary, Ian; Jia, Haiyan; Loehr, Marianne; Davis, Dana
PATENT ASSIGNEE(S): Ark Therapeutics Ltd., UK
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002034767	A1	20020502	WO 2001-GB4736		20011025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2426736	A1	20020502	CA 2001-2426736		20011025
AU 2002010713	A5	20020506	AU 2002-10713		20011025
EP 1328539	A1	20030723	EP 2001-978615		20011025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
HU 200301523	A2	20031028	HU 2003-1523		20011025
HU 200301523	A3	20061128			
JP 2004512342	T	20040422	JP 2002-537757		20011025
CN 1612893	A	20050504	CN 2001-817997		20011025
NO 2003001845	A	20030424	NO 2003-1845		20030424
US 2004054143	A1	20040318	US 2003-398616		20030806
PRIORITY APPLN. INFO.:			GB 2000-26134	A	20001025
			WO 2001-GB4736	W	20011025

ABSTRACT:
A peptide having part or all of the amino acid sequence QKRKRKKSRYKSWSVP (which is part of VEGF) has the ability to inhibit angiogenesis.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>